Lidocaine 5% Patch Supplementation to Intra-articular Bupivacaine Dexmedetomidine After Arthroscopic Knee Surgery

Dexmedetomidine Clinical Trial

Official title:

Effect of Lidocaine 5% Patch Supplementation to Intra-articular Bupivacaine Dexmedetomidine After Arthroscopic Knee Surgery Under General Anesthesia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04322760
• Other study ID #: 31084/07/16
• Status: Completed
• Phase: N/A
• Start date: December 1, 2016
• Est. completion date: December 1, 2017

Study information

• Verified date: March 2020
• Source: Tanta University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Surgery of the knee is a very common procedure which can be very painful and sufficient postoperative pain treatment is often problematic. The aim of this work was to study the effects of supplementation of intra-articular bupivacaine dexmedetomidine with lidocaine 5% patch after arthroscopic knee surgery under general anesthesia and its role in improving quality of anesthesia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: December 1, 2017
• Est. primary completion date: November 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Adult patients

• ASA I & II

• Aged between 18 to 60 years

• Weight between 60 to 100 kg

• Scheduled for elective arthroscopic knee surgery

Exclusion Criteria:

• patient refusal.

• history of cardiac disease.

• impaired renal or hepatic function.

• hypertension treated with a methyldopa, clonidine, or beta-adrenergic blockers.

• if they have used opioid analgesics within the previous 24 hr.

• previous sensitivity to local anesthetics.

Related Conditions & MeSH terms

• Arthroscopic Knee Surgery
• Dexmedetomidine
• Intra-articular
• Lidocaine 5% Patch

Intervention

Drug:
• Lidocaine 5% patch with Dexmedetomidine Bupivacaine
10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique and a patch of lidocaine 5% was applied to the skin between the arthroscopic ports
• Dexmedetomidine Bupivacaine
10 ml 0.5 % Bupivacaine and 1µg/kg Dexmedetomidine diluted in 10 ml saline was injected intra-articularly through one of the arthroscopic ports after the end of the surgery under complete aseptic technique without a patch of lidocaine 5%

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tanta University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The total dose of postoperative pethidine consumption	The total dose of postoperative pethidine consumption; Pethidine 20 mg was given as rescue analgesia if pain visual analogue visual analogue scale (VAS) =4.	24 hours
Secondary	First postoperative analgesia request time	First postoperative analgesia (Pethidine 20 mg) request time	24 hours
Secondary	Pain intensity	Visual analogue scale (VAS) was recorded immediately postoperative and at 30 min, 1, 2, 4, 6, 12 and 24 hours postoperatively. The score ranges from 0 to 10; higher means worse pain	24 hours